adMare BioInnovations Celebrates Successes of adMare Tx Accelerator Companies, Concludes Ontario Partnership with MaRS

Vancouver (BC), Toronto (ON), and Montreal (QC) – October 22, 2024 – adMare BioInnovations is proud to celebrate the ongoing success of its National adMare Tx Accelerator program in advancing early-stage Canadian therapeutic (Tx) companies towards successful commercialization, paving the way for significant patient and economic impact.

Since inception, the program has provided support for 13 innovative companies across a range of therapeutic areas with a bespoke combination of services tailored to accelerate drug and business development. The adMare Tx Accelerator is currently supporting six companies, all of which are progressing well toward key milestones and being recognized for their accomplishments.  SeraGene was recognized by Life Sciences BC as a 2024 Company to Watch. 9Bio, RejuvenRx and SeraGene were each selected to present their company at the Sweet BioPharmaDay event, and NorthMirs recently won $250,000 at ECHO PITCH 2024.

“It is exciting to see the significant strides made by the innovative companies within the program,” said Gordon McCauley, President and CEO of adMare BioInnovations. “This progress highlights the potential for real impact on patient lives globally and as a core driver of the Canadian economy”.

While continuing to focus on the growth of its accelerator companies, adMare is also announcing the conclusion of its partnership with MaRS Discovery District in Ontario. “We are committed to ensuring that MaRS’ withdrawal from the program will not affect the Ontario companies we support. We understand that MaRS priorities are elsewhere, and we look forward to future collaborations when the timing aligns.” said McCauley. “Meanwhile, adMare remains committed and open to partnership as we continue to expand the impact of the Tx Accelerator in Ontario and across Canada”.

The Tx Accelerator is open for applications across the country.  For more information on the adMare Tx Accelerator Program and to apply, visit https://www.admarebio.com/en/accelerator. 

-30-

For More Information

Media Contact
Mounia Azzi
Vice President, Corporate Development,
adMare BioInnovations
mazzi@admarebio.com

About adMare BioInnovations

With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare has helped build 36 companies, of which 25 are still active. These companies have attracted $2.4 billion of risk capital, have a combined value of $5.7 billion, and have created around 1,000 jobs in Canada. Our dynamic Montreal and Vancouver Innovation Centres have been home to 48 life science companies to date, with the 27 current resident companies employing over 350 life sciences professionals. The adMare Academy has trained more than 750 alumni — 92% of whom are employed in the life sciences industry. For more information, please visit www.admarebio.com.